Mochida Pharmaceutical: Summary of financial results for the 2nd quarter (interim period) of the fiscal year ending 2025/3 [Japanese GAAP] (consolidated)

JPXNov 1 01:00 ET · Announcements

Mochida Pharmaceutical 1H Net Y2.83B Vs Net Y2.84B

Dow JonesNov 1 01:00 ET

Asahi Kasei, TDK, Mitsui Chemicals, kddi corporation (1st day)

※Please note that the above calendar is subject to change depending on the company's circumstances.---------------------------------------November 1st (Friday)＜2229＞Calbee 　 　 　 ＜2282＞Nippon Ham＜2296＞Itoham Yonekyu Holdings 　 ＜2349＞NIID 　＜2440＞Gurunavi 　 　 　 ＜2480＞Sysmex＜2551＞MarsaInc 　 　＜2730＞Edion＜27

Fisco JapanOct 31 17:30 ET

Japanese Shares Drop as Investors Seek Safety Amid Middle East Tensions

MT NewswiresOct 2 02:30 ET

Nxera Pharma Partners With Shionogi to Market Insomnia Drug QUVIVIQ in Japan

MT NewswiresOct 1 22:33 ET

October 1st [Today's investment strategy]

[Fisco Selected Stocks] [Material Stocks] Nexera Pharma <4565> 1226 yen (10/1) Drug discovery venture. Former Sosei Group. Its subsidiary Nexera Pharma Japan has announced the signing of a partnership agreement with Shionogi <4507> regarding the distribution and sales of the insomnia treatment drug "Cubick Tablets" in Japan, and resolved its sales efforts with Mochida Pharmaceutical <4534>. Shionogi will independently conduct distribution and sales activities in Japan. [Emerging Markets]

Fisco JapanOct 1 19:37 ET